Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects

Journal of Clinical Investigation

Volumn 127, Issue 4, 2017, Pages 1338-1352

  Bekerman, Elena ^a   Neveu, Gregory ^a   Shulla, Ana ^b   Brannan, Jennifer ^c   Pu, Szu Yuan ^a   Wang, Stanley ^a   Xiao, Fei ^a   Barouch Bentov, Rina ^a   Bakken, Russell R ^c   Mateo, Roberto ^a   Govero, Jennifer ^d   Nagamine, Claude M ^a   Diamond, Michael S ^d   De Jonghe, Steven ^e   Herdewijn, Piet ^e   Dye, John M ^c   Randall, Glenn ^b   Einav, Shirit ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CORE PROTEIN; ERLOTINIB; PROTEIN TYROSINE KINASE; SUNITINIB; AAK1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; GAK PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRROLE DERIVATIVE; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CHIKUNGUNYA VIRUS; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG MECHANISM; DRUG POTENTIATION; EBOLA HEMORRHAGIC FEVER; ECTOPIC EXPRESSION; FEMALE; HEPATITIS C VIRUS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; JUNIN VIRUS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; RNA REPLICATION; RNA VIRUS; VERO CELL LINE; VIRUS ENTRY; VIRUS PARTICLE; VIRUS RELEASE; VIRUS STRAIN; WEST NILE VIRUS; 129 MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DENGUE VIRUS; DRUG EFFECTS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HEPACIVIRUS; HEPATITIS C; HUMAN; METABOLISM; PRECLINICAL STUDY; PROTEIN TRANSPORT; TUMOR CELL LINE; VIROLOGY;

ADAPTOR PROTEIN COMPLEX 1; ADAPTOR PROTEIN COMPLEX 2; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DENGUE; DENGUE VIRUS; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; EBOLAVIRUS; ERLOTINIB HYDROCHLORIDE; FEMALE; HEMORRHAGIC FEVER, EBOLA; HEPACIVIRUS; HEPATITIS C; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE, 129 STRAIN; MICE, INBRED C57BL; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; PYRROLES; VIRUS INTERNALIZATION;

EID: 85018228262     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI89857     Document Type: Article

References (73)

1. Bhatt S, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-507.
2. Flipse J, Smit JM. The complexity of a Dengue vaccine: a review of the human antibody response. PLoS Negl Trop Dis. 2015;9(6):e0003749.
3. Priyamvada L, et al. Human antibody responses after dengue virus infection are highly crossreactive to Zika virus. Proc Natl Acad Sci U S A. 2016;113(28):7852-7857.
4. Dejnirattisai W, et al. Dengue virus sero-crossreactivity drives antibody-dependent enhance-ment of infection with Zika virus. Nat Immunol. 2016;17(9):1102-1108.
5. Stettler K, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353(6301):823-826.
6. Henao-Restrepo AM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857-866.
7. Bekerman E, Einav S. Infectious disease. Combating emerging viral threats. Science. 2015;348(6232):282-283.
8. Park SY, Guo X. Adaptor protein complexes and intracellular transport. Biosci Rep. 2014;34(4):e00123.
9. Olusanya O, Andrews PD, Swedlow JR, Smythe E. Phosphorylation of threonine 156 of the mu2 subunit of the AP2 complex is essential for endocytosis in vitro and in vivo. Curr Biol. 2001;11(11):896-900.
10. Ricotta D, Conner SD, Schmid SL, von Figura K, Honing S. Phosphorylation of the AP2 mu subunit by AAK1 mediates high affinity binding to membrane protein sorting signals. J Cell Biol. 2002;156(5):791-795.
11. Umeda A, Meyerholz A, Ungewickell E. Identification of the universal cofactor (auxilin 2) in clathrin coat dissociation. Eur J Cell Biol. 2000;79(5):336-342.
12. Zhang CX, Engqvist-Goldstein AE, Carreno S, Owen DJ, Smythe E, Drubin DG. Multiple roles for cyclin G-associated kinase in clathrin-mediated sorting events. Traffic. 2005;6(12):1103-1113.
13. Ghosh P, Kornfeld S. AP-1 binding to sorting signals and release from clathrin-coated vesicles is regulated by phosphorylation. J Cell Biol. 2003;160(5):699-708.
14. Conner SD, Schmid SL. Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis. J Cell Biol. 2002;156(5):921-929.
15. Fingerhut A, von Figura K, Honing S. Binding of AP2 to sorting signals is modulated by AP2 phosphorylation. J Biol Chem. 2001;276(8):5476-5482.
16. Lee DW, Zhao X, Zhang F, Eisenberg E, Greene LE. Depletion of GAK/auxilin 2 inhibits receptormediated endocytosis and recruitment of both clathrin and clathrin adaptors. J Cell Sci. 2005;118(pt 18):4311-4321.
17. Alconada A, Bauer U, Hoflack B. A tyrosine-based motif and a casein kinase II phosphorylation site regulate the intracellular trafficking of the varicella-zoster virus glycoprotein I, a protein localized in the trans-Golgi network. EMBO J. 1996;15(22):6096-6110.
18. Bhattacharyya S, Hope TJ, Young JA. Differential requirements for clathrin endocytic pathway components in cellular entry by Ebola and Marburg glycoprotein pseudovirions. Virology. 2011;419(1):1-9.
19. Dutta D, et al. EphrinA2 regulates clathrin mediated KSHV endocytosis in fibroblast cells by coordinating integrin-associated signaling and c-Cbl directed polyubiquitination. PLoS Pathog. 2013;9(7):e1003510.
20. Huang HC, Chen CC, Chang WC, Tao MH, Huang C. Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J Virol. 2012;86(17):9443-9453.
21. Humphries AC, Dodding MP, Barry DJ, Collinson LM, Durkin CH, Way M. Clathrin potentiates vaccinia-induced actin polymerization to facilitate viral spread. Cell Host Microbe. 2012;12(3):346-359.
22. Neveu G, Barouch-Bentov R, Ziv-Av A, Gerber D, Jacob Y, Einav S. Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly. PLoS Pathog. 2012;8(8):e1002845.
23. Neveu G, Ziv-Av A, Barouch-Bentov R, Berkerman E, Mulholland J, Einav S. AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J Virol. 2015;89(8):4387-4404.
24. Ohka S, Ohno H, Tohyama K, Nomoto A. Basolateral sorting of human poliovirus receptor alpha involves an interaction with the mu1B subunit of the clathrin adaptor complex in polarized epithelial cells. Biochem Biophys Res Commun. 2001;287(4):941-948.
25. Ohno H, Aguilar RC, Fournier MC, Hennecke S, Cosson P, Bonifacino JS. Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family. Virology. 1997;238(2):305-315.
26. Agrawal T, Schu P, Medigeshi GR. Adaptor protein complexes-1 and 3 are involved at distinct stages of flavivirus life-cycle. Sci Rep. 2013;3:1813.
27. Karaman MW, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127-132.
28. Kovackova S, et al. Selective inhibitors of cyclin G Associated Kinase (GAK) as anti-hepatitis C agents. J Med Chem. 2015;58(8):3393-3410.
29. Benedicto I, et al. Clathrin mediates infectious hepatitis C virus particle egress. J Virol. 2015;89(8):4180-4190.
30. Coller KE, Heaton NS, Berger KL, Cooper JD, Saunders JL, Randall G. Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog. 2012;8(1):e1002466.
31. Sorensen EB, Conner SD. AAK1 regulates Numb function at an early step in clathrin-mediated endocytosis. Traffic. 2008;9(10):1791-1800.
32. Coller KE, Heaton NS, Berger KL, Cooper JD, Saunders JL, Randall G. Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog. 2012;8(1):e1002466.
33. Wacker I, Kaether C, Krömer A, Migala A, Almers W, Gerdes HH. Microtubule-dependent transport of secretory vesicles visualized in real time with a GFP-tagged secretory protein. J Cell Sci. 1997;110(pt 13):1453-1463.
34. Yang CC, et al. Characterization of an efficient dengue virus replicon for development of assays of discovery of small molecules against dengue virus. Antiviral Res. 2013;98(2):228-241.
35. Kostich W et al. Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain. J Pharmacol Exp Ther. 2016;358(3):371-386.
36. van Cleef KW, et al. Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication. Antiviral Res. 2013;99(2):165-171.
37. Bhattacharyya S, Mulherkar N, Chandran K. Endocytic pathways involved in filovirus entry: advances, implications and future directions. Viruses. 2012;4(12):3647-3664.
38. Poirier S, et al. The cytosolic adaptor AP-1A is essential for the trafficking and function of Niemann-Pick type C proteins. Traffic. 2013;14(4):458-469.
39. Carette JE, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 2011;477(7364):340-343.
40. Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. J Virol. 1999;73(1):783-786.
41. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis. 2007;195(5):665-674.
42. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27-31.
43. Mendel DB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-337.
44. Higgins B, et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs. 2004;15(5):503-512.
45. Haznedar JO, et al. Single-and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol. 2009;64(4):691-706.
46. Chee EL, Lim AY, Modamio P, Fernandez-Lastra C, Segarra I. Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. Eur J Drug Metab Pharmacokinet. 2016;41(3):309-319.
47. Zerbe LK, et al. Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother Pharmacol. 2008;62(4):605-620.
48. Orozco S, et al. Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J Gen Virol. 2012;93(pt 10):2152-2157.
49. Human Kinome Heat Map. SuperNova Life Science. http://www.supernovalifescience.com/ HM/HM%2041.pdf. Accessed January 11, 2017.
50. Davis MI, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29(11):1046-1051.
51. Rathore AP, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res. 2011;92(3):453-460.
52. Brindley MA, et al. Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein. Virology. 2011;415(2):83-94.
53. Meertens L, et al. The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe. 2012;12(4):544-557.
54. Hamel R, et al. Biology of Zika virus infection in human skin cells. J Virol. 2015;89(17):8880-8896.
55. Nowakowski TJ, Pollen AA, Di Lullo E, Sandoval-Espinosa C, Bershteyn M, Kriegstein AR. Expression analysis highlights AXL as a candidate Zika virus entry receptor in neural stem cells. Cell Stem Cell. 2016;18(5):591-596.
56. Roskoski R. Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun. 2005;337(1):1-13.
57. Scagliotti GV, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol. 2012;30(17):2070-2078.
58. Blumenschein GR, et al. Sunitinib plus erlotinib for the treatment of advanced/metastatic nonsmall-cell lung cancer: a lead-in study. J Thorac Oncol. 2012;7(9):1406-1416.
59. Chipwaza B, et al. Dengue and Chikungunya fever among viral diseases in outpatient febrile children in Kilosa district hospital, Tanzania. PLoS Negl Trop Dis. 2014;8(11):e3335.
60. Karthik R, Vineetha KR, Raut CG. Seroprevalance of dengue and chikungunya co infection and its clinical correlation in bangalore city hospitals. Int J Curr Res. 2014;6(12):11040-11044.
61. Dupont-Rouzeyrol M, et al. Co-infection with Zika and dengue viruses in 2 patients, New Caledonia, 2014. Emerging Infect Dis. 2015;21(2):381-382.
62. de Wispelaere M, LaCroix AJ, Yang PL. The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J Virol. 2013;87(13):7367-7381.
63. Lin K, Gallay P. Curing a viral infection by targeting the host: the example of cyclophilin inhibitors. Antiviral Res. 2013;99(1):68-77.
64. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010;10(2):130-137.
65. Rual JF, et al. Human ORFeome version 1.1: a platform for reverse proteomics. Genome Res. 2004;14(10B):2128-2135.
66. Heaton NS, Randall G. Dengue virus-induced autophagy regulates lipid metabolism. Cell Host Microbe. 2010;8(5):422-432.
67. Tscherne DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, Rice CM. Time-and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol. 2006;80(4):1734-1741.
68. Zou G, Xu HY, Qing M, Wang QY, Shi PY. Development and characterization of a stable luciferase dengue virus for high-throughput screening. Antiviral Res. 2011;91(1):11-19.
69. Huang CY, et al. The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion. Virology. 2010;396(2):305-315.
70. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science. 2005;308(5728):1643-1645.
71. Prestwood TR, Prigozhin DM, Sharar KL, Zellweger RM, Shresta S. A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. J Virol. 2008;82(17):8411-8421.
72. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003;197(5):633-642.
73. Prichard MN, Shipman C. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir Ther (Lond). 1996;1(1):9-20.